Tenofovir Disoproxil

Catalog No.S5959 Synonyms: Bis(POC)-PMPA, GS 4331

For research use only.

Tenofovir Disoproxil (Bis(POC)-PMPA, GS 4331) is a prodrug of tenofovir, which is metabolised intracellularly to its active anabolite tenofovir diphosphate, a competitive inhibitor of HIV-1 reverse transcriptase and terminates the growing DNA chain.

Tenofovir Disoproxil Chemical Structure

CAS No. 201341-05-1

Selleck's Tenofovir Disoproxil has been cited by 2 Publications

Purity & Quality Control

Choose Selective Reverse Transcriptase Inhibitors

Other Reverse Transcriptase Products

Biological Activity

Description Tenofovir Disoproxil (Bis(POC)-PMPA, GS 4331) is a prodrug of tenofovir, which is metabolised intracellularly to its active anabolite tenofovir diphosphate, a competitive inhibitor of HIV-1 reverse transcriptase and terminates the growing DNA chain.
Targets
Reverse Transcriptase [1]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 519.44
Formula

C19H30N5O10P

CAS No. 201341-05-1
Storage 3 years -20°C powder
2 years -80°C in solvent

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03576066 Completed Drug: ABI-H0731|Drug: SOC NUC|Drug: Placebo Oral Tablet Chronic Hepatitis B Assembly Biosciences June 11 2018 Phase 2
NCT03361956 Completed Drug: JNJ-56136379|Drug: Placebo|Drug: NA (ETV or TDF) Hepatitis B Janssen Sciences Ireland UC February 13 2018 Phase 2
NCT02985996 Completed Drug: Truvada|Drug: Genvoya HIV Infections Emory University|Centers for Disease Control and Prevention February 6 2017 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Tenofovir Disoproxil | Tenofovir Disoproxil supplier | purchase Tenofovir Disoproxil | Tenofovir Disoproxil cost | Tenofovir Disoproxil manufacturer | order Tenofovir Disoproxil | Tenofovir Disoproxil distributor